Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Opiant Pharmaceuticals Inc
(NQ:
OPNT
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Mar 1, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Opiant Pharmaceuticals Inc
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
February 07, 2023
From
Opiant Pharmaceuticals, Inc.
Via
GlobeNewswire
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
February 06, 2023
From
Opiant Pharmaceuticals, Inc.
Via
GlobeNewswire
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
January 19, 2023
From
Opiant Pharmaceuticals, Inc.
Via
GlobeNewswire
OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant Pharmaceuticals, Inc. - OPNT
January 06, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. (Nasdaq - APEN), Imago BioSciences, Inc. (Nasdaq - IMGO), Opiant Pharmaceuticals Inc. (Nasdaq - OPNT), Benefitfocus, Inc. (Nasdaq - BNFT)
December 05, 2022
From
Brodsky & Smith LLC
Via
GlobeNewswire
OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant Pharmaceuticals, Inc. - OPNT
November 14, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Opiant Pharmaceuticals (NASDAQ: OPNT) Enters Into Definitive Agreement to be Acquired by Indivior for $145 Million
November 14, 2022
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) is engaged as a specialty pharmaceutical company, which is focused on developing treatments for drug
Via
Spotlight Growth
OPNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Opiant Pharmaceuticals, Inc. Is Fair to Shareholders
November 14, 2022
From
Halper Sadeh LLC
Via
Business Wire
Small-Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)
June 06, 2022
Via
AB Newswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.